Pharmacovigilance (PV), also called drug safety, is the science of finding, judging and preventing the harmful effects of medicines. It starts in clinical trials and lasts as long as a medicine is sold. PV teams collect reports of side effects and code them with MedDRA. They judge whether the medicine caused each one, look for new warning signs, and report to regulators such as CDSCO in India, the FDA and the EMA.
Key takeaways
- The word comes from Greek “pharmakon” (medicine) and Latin “vigilare” (to keep watch).
- The thalidomide tragedy led WHO to start its International Drug Monitoring Programme in 1968.
- India’s national system is the Pharmacovigilance Programme of India (PvPI), started in 2010.
- The core process: collect → enter and code → assess → detect signals → manage risk → report.
- Drug Safety Associate is the most common first job for pharmacy and life science graduates.
On this page ⌄
What is pharmacovigilance?
Pharmacovigilance, also known as drug safety, is the work of monitoring, evaluating and preventing the harmful effects of medicines. The word comes from the Greek “pharmakon” (medicine) and the Latin “vigilare” (to keep watch) — so it literally means “keeping watch over medicines”.
It covers side effects, medication errors, misuse, lack of effect and other problems with medicines. The aim is simple: keep every medicine safe and useful for its whole life, from the first trials to years of use by the public.
Why does drug safety matter?
Every medicine carries some risk. Some risks show up only after many thousands of people have used it, because trials are too small and too short to find every rare side effect. Drug safety work fills that gap. It helps to:
- Find side effects that were not known before
- Measure how often and how severe known side effects are
- Make sure a medicine’s benefits still outweigh its risks
- Guide regulators’ decisions — label changes, warnings or, rarely, withdrawal
It is also a global effort. National regulators such as the US FDA, the European Medicines Agency and India’s PvPI share safety data through the World Health Organization.
A short history of drug safety
- 1
Late 1950s – early 1960s: thalidomide
Thalidomide, given to pregnant women for morning sickness, caused severe birth defects in thousands of babies. It showed that medicines must be watched even after approval.
- 2
1968: WHO programme begins
WHO launched its Programme for International Drug Monitoring to pool adverse reaction reports from many countries.
- 3
1970s–1990s: national systems grow
The USA, the UK and later the European Medicines Agency built their own drug safety systems, with stricter rules for trials, post-marketing surveillance and reporting.
- 4
2010: PvPI in India
India launched the Pharmacovigilance Programme of India. Its National Coordination Centre is at the Indian Pharmacopoeia Commission in Ghaziabad.
- 5
Today: a global network
WHO’s VigiBase holds over 40 million reports from 180+ member countries, covering nearly 99% of the world’s population (UMC, 2025).
The pharmacovigilance process, step by step
Drug safety teams follow the same basic cycle for every report:
What happens
- 1. Case intake and triage
- Receive the report, check it is valid, and flag serious cases first
- 2. Data entry and coding
- Enter the case in a safety database and code terms with MedDRA
- 3. Medical review
- Assess seriousness, expectedness and whether the medicine caused the event (causality)
- 4. Signal detection
- Look across many reports for new or unusual patterns
- 5. Risk management
- Reduce the risk through label changes, warnings or restrictions
- 6. Reporting and communication
- Report to regulators on time and inform doctors and patients
Example
- 1. Case intake and triage
- A hospital reports a death possibly linked to a new painkiller — triaged as serious and urgent
- 2. Data entry and coding
- “Upset stomach” is coded to the MedDRA term “Dyspepsia”
- 3. Medical review
- A reviewer checks if liver damage was due to the drug or another illness
- 4. Signal detection
- Several reports of seizures after a new cough syrup trigger a signal
- 5. Risk management
- A cancer drug’s plan requires regular heart monitoring
- 6. Reporting and communication
- A new warning is sent to doctors and added to the label
Reports come from doctors, nurses, pharmacists and patients. They also come from trials, studies after launch, medical journals and, more and more, apps.
Key terms, with examples
1What is an adverse drug reaction (ADR)?
A harmful response to a medicine that was not intended, where the medicine is a likely cause. Example: a bad skin rash after an antibiotic.
2What is an adverse event (AE)?
Any unwanted health event after taking a medicine, whether or not the medicine caused it. Example: a headache after a vitamin tablet. Every ADR is an AE, but not every AE is an ADR.
3What is a serious adverse event (SAE)?
An event that causes death or is life-threatening. It also counts if it needs a hospital stay, causes lasting disability or a birth defect, or is medically important.
4What is a safety signal?
A hint of a new possible risk, or something new about a known risk. It needs more checking. A signal is not proof of harm.
5What is causality assessment?
Deciding how likely it is that a medicine caused an event. Reviewers look at timing, dose and other causes, and use tools such as the WHO-UMC system or the Naranjo scale.
6What is MedDRA?
The Medical Dictionary for Regulatory Activities. It is a standard list of medical terms used to code side effects, so data from around the world can be compared. Example: “stomach pain” is always coded the same way.
7What is spontaneous reporting?
Reports of suspected side effects that doctors or patients send by choice. For example, a doctor reports a skin reaction to PvPI. It is the main early warning source.
8What is a Risk Management Plan (RMP)?
A company document that lists a medicine’s known and possible risks, and how they will be watched and reduced. The EU asks for one with every new application to sell a medicine.
9What is a PSMF?
The Pharmacovigilance System Master File. It describes a company’s whole PV system: its people, steps and databases. Inspectors use it during audits.
10What are PSURs and PBRERs?
Regular reports to regulators that sum up a medicine’s safety data and whether its benefits still outweigh its risks. ICH E2C(R2) sets the PBRER format.
11What is a QPPV?
The Qualified Person Responsible for Pharmacovigilance — the person legally responsible for a company’s PV system in the European Union. India’s CDSCO guidance uses a similar role, the Pharmacovigilance Officer In-charge (PvOI).
12What is VigiBase?
WHO’s global database of adverse event reports for medicines and vaccines, run by the Uppsala Monitoring Centre in Sweden. India contributes through PvPI.
Drug safety across a medicine’s life
Who takes part
- Phase I
- 20–100 healthy volunteers or patients
- Phase II
- Up to several hundred patients
- Phase III
- 300–3,000 patients
- Phase IV (post-marketing)
- Everyone who uses the approved medicine
Safety focus
- Phase I
- Safety and dose range; immediate reactions
- Phase II
- Effectiveness and side effects in people with the condition
- Phase III
- Confirms benefit and finds less common side effects
- Phase IV (post-marketing)
- Long-term safety and rare reactions in real-world use
Sizes follow the US FDA’s description of trial phases. Some side effects appear only in Phase IV, once children, older people and people with other illnesses use the medicine. That is why watching a medicine after launch matters so much.
Pharmacovigilance regulations in India and worldwide
Authority
- India
- CDSCO and PvPI (IPC)
- USA
- FDA
- European Union
- EMA
- Japan
- PMDA
- Global
- ICH, WHO, CIOMS
What to know
- India
- Report serious ADRs within 15 days. PSURs every 6 months for the first 2 years after approval, then yearly for 2 years. Companies keep a PSMF and appoint a PV Officer In-charge (PvOI).
- USA
- MedWatch for reporting; FAERS database. Serious and unexpected reactions go in 15-day Alert reports. High-risk drugs may need REMS.
- European Union
- Good Pharmacovigilance Practices (GVP) modules; EudraVigilance database; every company needs a QPPV.
- Japan
- Collects reports and runs post-marketing safety measures; follows ICH standards.
- Global
- ICH E2A (expedited reporting), E2B (electronic case reports), E2C(R2) (PBRER), E2D (post-approval safety data), E2E (PV planning); WHO runs VigiBase.
In India, anyone can report a suspected side effect to PvPI — patients too. Use the ADR form, the ADR PvPI mobile app or the toll-free number 1800-180-3024. Reports go through hundreds of ADR monitoring centres in medical colleges and hospitals.
Tools and databases
Argus Safety (Oracle)
A widely used company safety database for case processing, coding, review and submissions.
ARISg / LifeSphere (ArisGlobal)
Safety database for case processing, ICSR submissions and analytics.
VigiFlow (UMC)
Web-based system national centres use to manage reports and send them to VigiBase — used by PvPI.
VigiBase and EudraVigilance
WHO’s global database and the EU’s database, used for signal detection.
MedDRA
Not a database but a coding dictionary for adverse events, maintained by the MSSO.
Analytics tools
SAS, Python, Power BI and AI tools for signal detection, dashboards and literature screening.
At BCRI you practise case processing on the Clinevo safety database. See our safety database training.
Challenges and trends
Response
- Under-reporting of side effects
- Mobile apps such as ADR PvPI, awareness campaigns, patient reporting
- Data overload and duplicate reports
- Automation and AI-assisted case processing
- Different rules in different countries
- ICH guidelines and WHO collaboration
- New biologics and gene therapies
- Specialised monitoring plans and training
- Side effects discussed on social media
- Monitoring of digital sources with human review
Data from health records is also shaping drug safety. So is pharmacogenomics, which uses genes to predict who may react badly to a medicine. Learn more on our AI in clinical research page.
Careers in pharmacovigilance
PV is a popular career for graduates in pharmacy, life sciences, biotechnology, medicine and nursing. Freshers can start in entry-level roles after training.
What you do
- Drug Safety Associate
- Case intake, data entry, MedDRA coding, quality checks
- PV Officer / Executive
- Timelines, SOPs, audits and team support
- Medical Reviewer
- Causality, expectedness and clinical assessment
- Safety Data Analyst
- Trends, dashboards and signal detection
- Aggregate Report Specialist
- PSURs, PBRERs and DSURs
- QPPV / PvOI
- Legal responsibility for the PV system
Typical background
- Drug Safety Associate
- Pharmacy and life science freshers
- PV Officer / Executive
- 2–4 years of PV experience
- Medical Reviewer
- MBBS, MD, BDS or Pharm.D
- Safety Data Analyst
- Analytics or biostatistics
- Aggregate Report Specialist
- Experienced PV professionals
- QPPV / PvOI
- Senior PV or regulatory leaders
Pay varies by employer and city. AmbitionBox reports Drug Safety Associates in Bengaluru earning about ₹3.8–4.2 lakh a year with 0–4 years of experience (October 2026).
Companies with PV teams in India include IQVIA, Parexel, Accenture, Cognizant, TCS, APCER Life Sciences and Lambda Therapeutic Research. You will need clear written English and basic medical terms. Knowing the main rules, MedDRA, narrative writing and a safety database helps a lot. Some jobs involve shift work.
How to start your career
- 1
Learn the basics
Understand ADRs, seriousness, causality, MedDRA and the ICH E2 guidelines — this guide is a good start.
- 2
Get practical training
Practise case processing, MedDRA coding and narrative writing on a real safety database.
- 3
Prepare for interviews
Revise the most common questions with our top 21 pharmacovigilance interview questions.
- 4
Apply for Drug Safety Associate roles
Target CROs, pharma companies and PV service providers.
Train with BCRI
Our 2-month pharmacovigilance training covers case processing, MedDRA coding and safety database practice, online or in Bangalore, with placement assistance. Want practical experience too? See our pharmacovigilance internship program.
BCRI students now working in drug safety and clinical research
Recent placements published on the BCRI Career Hub.
PlacementSreekutty Shaji
Project support coordinator 2 · PPD
PlacementReenu
Investigators grants specialist · Novotech
PlacementGowthami sree
Clinical Research Coordinator · Max Clinical Research
PlacementReethika
QA specialist · Weltrix Biometrics
Placements across BCRI programmes. Placement assistance, not a job guarantee. See all on the Career Hub
FAQs
What is the meaning of pharmacovigilance?
Pharmacovigilance means “keeping watch over medicines”. It is the science and activities of detecting, assessing, understanding and preventing the harmful effects of medicines.
What are the main steps in the pharmacovigilance process?
Case intake and triage, data entry and MedDRA coding, medical review and causality assessment, signal detection, risk management, and reporting to regulators.
What is PvPI?
The Pharmacovigilance Programme of India, started in 2010. Its National Coordination Centre is the Indian Pharmacopoeia Commission in Ghaziabad, and it works with CDSCO and WHO.
How can a patient report a side effect in India?
Use PvPI’s ADR reporting form, the ADR PvPI mobile app or the toll-free number 1800-180-3024, or tell your doctor or pharmacist.
Who can work in pharmacovigilance?
Graduates in pharmacy, life sciences, biotechnology, medicine, dentistry, AYUSH and nursing. Freshers usually start as Drug Safety Associates after training.
Is pharmacovigilance a good career?
Yes, for people who like medicine, detail and writing. Every medicine needs safety monitoring for its whole life, so CROs, pharma companies and service providers hire PV professionals regularly.
Can I download these pharmacovigilance notes?
Yes. Use the Save as PDF button at the top of the page and choose “Save as PDF” in your browser’s print window.